PRAXIS PRECISION MEDICINE Q2 2026 EARNINGS CALL SUMMARY

1Key Financial Results and Metrics

Operating Expenses: $96.9 million (up from $76 million in Q2 2025), with R&D expenses at $69.4 million and G&A at $27.5 million.

Cash Position: Ended Q2 with $1.4 billion in cash, cash equivalents, and marketable securities, compared to $926 million as of December 31, 2025, providing a runway into 2028.

Operating Cash Burn: Increased to $78 million in Q2 2026 from $55 million in Q2 2025, reflecting higher spending in R&D and G&A.

2Strategic Updates and Business Highlights

Regulatory Progress: Two NDAs (ulixacaltamide for essential tremor and relutrigine for SCN2A and SCN8A epilepsies) are in late-stage review with the FDA, with approvals expected in approximately six months.

Commercial Readiness: Established commercial leadership and a field force for upcoming launches, with a distribution network and inventory being built.

Ulixacaltamide: Positioned to be the first FDA-approved therapy for essential tremor, with a potential launch by January 2027. The FDA's mid-cycle review was positive, with no significant efficacy-related issues identified.

Relutrigine: Expected to be the first therapy for SCN2A and SCN8A-DEE, with a new PDUFA target of December 27, 2026, following a major amendment submission.

Collaboration: Announced a partnership with Remagine Labs to enhance the value of ulixacaltamide beyond its initial launch.

3Forward Guidance and Outlook

Launch Preparations: Both ulixacaltamide and relutrigine are on track for successful launches, with comprehensive patient support programs in place.

Market Potential: Ulixacaltamide's peak sales potential is estimated at around $10 billion, with a target patient population of approximately 2 million.

Sales Force: Plans to build a sales force of about 300 representatives to target neurologists primarily, with a focus on ensuring a high-quality patient experience.

4Bad News, Challenges, or Points of Concern

Vormatrigine Study Results: The POWER1 study did not meet its primary endpoint, leading to a revamp of the POWER2 and POWER3 studies. While secondary endpoints showed promise, the primary endpoint miss raises concerns about the drug's efficacy.

Regulatory Risks: Although the FDA's feedback has been positive, the company remains cautious about future regulatory discussions and the potential for changes in labeling.

Market Competition: The company faces competition in the epilepsy treatment market, particularly with other sodium channel blockers, which may affect market penetration.

5Notable Q&A Insights

Sales Force Composition: The sales team for relutrigine is comprised of experienced individuals with a focus on rare neurological conditions, with a strong emphasis on launch readiness.

Payer Engagement: Positive feedback from payers regarding the need for ulixacaltamide, with plans for step edits in coverage being considered.

Patient Population for Relutrigine: The focus will be on a broad patient population, with careful use to ensure proper assessment before treatment initiation.

Titration Strategy: Confidence in the proposed titration strategy for ulixacaltamide is based on data suggesting that longer patient retention leads to better outcomes, despite the challenges of tolerability. Overall, Praxis Precision Medicine is positioned for significant growth with upcoming product launches, although it must navigate regulatory hurdles and competitive pressures in the market.